|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis?显示文摘AIM:To investigate the effectiveness of rectally administered indomethacin in the prophylaxis of post-endoscopic retrograde cholangiopancreatography(ERCP)pancreatitis and hyperamylasaemia in a multicentre study.METHODS:A prospective,randomised,placebocontrolled multicentre study in five endoscopic units was conducted on 686 patients randomised to receive a suppository containing 100 mg indomethacin,or an inert placebo,10-15 min before ERCP.Post-ERCP pancreatitis and hyperamylasaemia were evaluated 24 h following the procedure on the basis of clinical signs and laboratory parameters,and computed tomography/magnetic resonance imaging findings if required.RESULTS:Twenty-one patients were excluded because of incompleteness of their data or because of protocol violation.The results of 665 investigations were evaluated:347 in the indomethacin group and 318 in the placebo group.The distributions of the risk factors in the two groups did not differ significantly.Pancreatitis developed in 42 patients(6.3%):it was mild in34(5.1%)and severe in eight(1.2%)cases.Hyperamylaesemia occurred in 160 patients(24.1%).There was no significant difference between the indomethacin and placebo groups in the incidence of either postERCP pancreatitis(5.8%vs 6.9%)or hyperamylasaemia(23.3%vs 24.8%).Similarly,subgroup analysis did not reveal any significant differences between the two groups.CONCLUSION:100 mg rectal indomethacin administered before ERCP did not prove effective in preventing post-ERCP pancreatitis. | Zoltán Dbrnte Zoltán Szepes Ferenc Izbéki Judit Gervain László Lakatos Gyula Pécsi Miklós Ihász Lilla Lakner Erzsébet Toldy László Czakó | 2014 | World Journal of Gastroenterology2014，20，29： | 16 |
| 2 | Relevance of α-defensins(HNP1-3) and defensin β-1 in diabetes显示文摘AIM: To investigate the genetic background of human defensin expression in type 1 and 2 diabetes.METHODS: Associations between DEFA1/DEFA3 gene copy number polymorphism and diabetes as well as between the promoter polymorphisms of DEFB1 and diabetes were studied. The copy number variation of the DEFA1/DEFA3 genes was determined in 257 diabetic patients(117 patients with type 1 and 140 with type 2 diabetes). The control group consisted of 221 age- and gender-matched healthy blood donors. The cumulative copy numbers of the DEFA1/DEFA3 genes were detected by using quantitative PCR analysis. To evaluate the HNP 1-3(human neutrophil peptide 1-3 or α-defensin) levels in the circulation, plasma HNP 1-3 concentrations were measured by ELISA. The expression of DEFA1/A3 in peripheral leukocytes of the diabetic patients was measured by quantitative RT PCR analysis. Three SNPs of the human DEFB1(human defensin β-1) gene: DEFB1 G-20A(rs11362), DEFB1 C-44G(rs1800972) and DEFB1 G-52A(rs1799946) were genotyped by Custom TaqMan? Real Time PCR assay.RESULTS: Significant differences were observed in HNP1-3 levels between the healthy subjects and both groups of diabetic patients. The mean ± SE was 28.78 ± 4.2 ng/mL in type 1 diabetes, and 29.82 ± 5.36 ng/mL in type 2 diabetes, vs 11.94 ± 2.96 ng/mL in controls; P < 0.01 respectively. There was no significant difference between patients with type 1 and type 2 diabetes in the high plasma concentrations of HNP1-3. The highest concentrations of α-defensin were found in diabetic patients with nephropathy(49.4 ± 4.8 ng/mL), neuropathy(38.7 ± 4.8 ng/mL) or cardiovascular complications(45.6 ± 1.45 ng/L). There was no significant difference in the cumulative copy numbers of DEFA1/DEFA3 genes between controls and patients, or between patients with the two types of diabetes. Comparisons of HNP 1-3 plasma level and DEFA1/A3 copy number of the same patient did not reveal significant relationship between defensin-α levels and the gene copy numbers(r2 = 0.01). Similarly, no positive correlation was observed between the copy numbers and the mRNA expression levels of DEFA1/A3. Regarding the C-44G polymorphism of DEFB1, the GG 'protective' genotype was much less frequent(1%-2%) among both groups of patients than among controls(9%).CONCLUSION: Elevated HNP1-3 levels in diabetes are independent of DEFA1/DEFA3 copy numbers, but GG genotype of C-44G SNP in DEFB1 gene may result in decreased defensin β-1 production. | Balázs Csaba Németh Tamás Várkonyi Ferenc Somogyvári Csaba Lengyel Katalin Fehértemplomi Szabolcs Nyiraty Péter Kempler Yvette Mándi | 2014 | World Journal of Gastroenterology2014，20，27： | 4 |
| 3 | Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy显示文摘AIM:To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn’s disease(CD)and ulcerative colitis(UC).METHODS:The data from 41 patients with CD and 22 patients with UC were assessed.Twenty-four CD patients received infliximab,and 17 received adalimumab.The endoscopic severity of CD was quantified with the simplified endoscopic activity score for Crohn’s disease in CD and with the Mayo endoscopic subscore in UC.RESULTS:Mucosal healing was achieved in 23 CD and7 UC patients.Biological therapy had to be restarted in78%of patients achieving complete mucosal healing with CD and in 100%of patients with UC.Neither clinical remission nor mucosal healing was associated with the time to restarting the biological therapy in either CD or UC.CONCLUSION:Mucosal healing did not predict sustained clinical remission in patients in whom the biological therapies had been stopped. | Klaudia Farkas Péter László Lakatos Mónika Szcs va Pallagi-Kunstár Anita Bálint Ferenc Nagy Zoltán Szepes Noémi Vass Lajos S Kiss Tibor Wittmann Tamás Molnár | 2014 | World Journal of Gastroenterology2014，20，11： | 2 |
| 4 | Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitisB using HBsAg and HBV DNA levels 显示文摘 | Rijckborst V Hansen BE Cakaloglu Y Ferenci P Tabak F Akdogan M Simon K Akarca US Flisiak R Verhey E Van Vuuren AJ Boucher CA ter Borg MJ Janssen HL | 2010 | Hepatology2010，52，2： | 1 |
| 5 | Detection of the His1069Gln mutation in Wilson' s disease by rapid poly- merase chain reaction显示文摘 | Maier-Dobeersberger T Ferenci P Polli C | 1997 | Ann Intern Med1997，127，1： | 1 |
| 6 | Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats:characterization of an improved model and study of amino acidergic neurotransmission 显示文摘 | ZIMMERMANN C FERENCI P PIFL C | 1989 | Hepatology1989，9，4： | 1 |
| 7 | Hepato eellular carcinoma (HCC):a global perspective显示文摘 | Ferenci P Fried M Labrecque D | 2010 | J Clin Gastroenterol2010，44，4： | 1 |
| 8 | The controversy of the treatment of critically ill patients with thyroid hormone显示文摘 | Ferenci P Lockwood A Mullen K | 2001 | Best Pract Res Cl in Endocrinol Metab2001，15，： | 1 |
| 9 | Hepatic encephalopathy- definition, nomenclature, diagnosis, and quantification: final report of the working party at the llth World Congresses of Gastroen- terology显示文摘 | Ferenci P Lockwood A Mullen K | 2002 | Hepatology2002，35，3： | 1 |
| 10 | Diagnosis and phenotypic classification of Wilson disease 显示文摘 | Ferenci P Caca K Loudianos G | 2003 | Liver Int2003，23，3： | 1 |
| 11 | Hepatic eneephalopathydefinition, nomenclature,diagnosis, and quantification: final report of the working party at the 11 th world congresses of gastroenterology, Vienna 1998 显示文摘 | Ferenci P Lockwood A Mullen K | 2002 | Hepatology2002，35，3： | 1 |
| 12 | Pathophysiology and clinical features of Wilson disease显示文摘 | Ferenci P | 2004 | Metab Brain Dis2004，19，34： | 1 |
| 13 | Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells显示文摘 | Ferenc P Solar P Kleban J | 2010 | J Photochem Photobiol B2010，98，1： | 1 |
| 14 | Artificial neural network approach for predicting transient water levels in a multilayered groundwater system under variable state, pumping, and climate conditions显示文摘 | EMERY C J FERENC S MARY P | 2003 | Journal of Hydrologic Engineering2003，8，6： | 1 |
| 15 | Review article:diagnosis and current therapy of Wilson's disease显示文摘 | Ferenci P | | 0，，： | 1 |
| 16 | Hepatic encephalopathy - defi- nition, nomenclature, diagnosis and quantification:final report of the Working Party at the 11 th World Congresses of Gastroenterology, Vienna 显示文摘 | Ferenci P Lockwood A Mullen K | 2002 | Hepatology2002，35，3： | 1 |
| 17 | Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells显示文摘 | Ferenc P Solar P Kleban J | 2010 | J Photochem Photobiol B2010，98，1： | 1 |
| 18 | Hepatic encephalopathy-definition,nomenclature,diagnosis,and quantification:final report of the working party at the 11th world congresses of gastroenterology,Vienna,1998显示文摘 | FERENCI P LOCKWOOD A MULLEN K | 2002 | Hepatolngy2002，35，3： | 1 |
| 19 | Clinical presentation, diagnosisand long-term outcome of Wilson s disease: a cohort study 显示文摘 | Merle U Schaefer M Ferenci P | 2007 | Gut2007，56，1： | 1 |
| 20 | Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders 显示文摘 | Rijckborst V Ferenci P Akdogan M | 2012 | Eur J Gastroenterol Hepatol2012，24，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员